Lyell Immunopharma
LYEL
99 hedge funds and large institutions have $389M invested in Lyell Immunopharma in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 16 closing their positions.
40% more capital invested
Capital invested by funds: $278M → $389M (+$111M)
0.09% more ownership
Funds ownership: 2.36% → 2.45% (+0.09%)
0% more funds holding
Funds holding: 99 → 99 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
9% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 34
91% less call options, than puts
Call options by funds: $1K | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
| 3 |
BlackRock
New York
|
+$2.06M |
| 4 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$1.06M |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
+$752K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$4.84M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.29M |
| 3 |
JP Morgan Chase
New York
|
-$1.08M |
| 4 |
Two Sigma Investments
New York
|
-$914K |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$830K |
LYEL Hedge Fund Activity: Q2 2023 in Review
99 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q2 2023, worth a combined $389M — up 40% from $278M a quarter earlier.
Fund positioning in LYEL was balanced in Q2 2023: 16 funds opened new positions, 16 closed out, 31 added to existing stakes and 34 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $11.6M. The largest seller was State Street, cutting an estimated $4.84M.
- 99 institutional investors held Lyell Immunopharma (LYEL) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $389M of Lyell Immunopharma stock for Q2 2023, up 40% quarter-over-quarter.
- 16 funds opened new Lyell Immunopharma positions in Q2 2023 and 16 closed out, a net change of 0 holders.
- The largest Lyell Immunopharma buyer in Q2 2023 was T. Rowe Price Associates, an estimated $11.6M added.
- The largest Lyell Immunopharma seller in Q2 2023 was State Street, an estimated $4.84M sold.
Based on aggregated 13F filings for Q2 2023.